Retina may be a potential biomarker for reduced brain matter according to new study
Researchers from the Department of Ophthalmology at the University Hospital Bonn and Deutsches Zentrum für Neurodegenerative Erkrankungen suggest that assessments of the eye’s retina could help to detect a loss of brain substance, ie “brain atrophy.” The findings are based on data from the Rhineland Study.
Phase 2 clinical trial of ADX-2191 for retinitis pigmentosa begins
The clinical trial will evaluate the safety and tolerability of ADX-2191 in patients diagnosed with RP due to mutations of the rhodopsin gene, including the P23H gene mutation.
Foundation Fighting Blindness, InformedDNA screening patients for pivotal clinical trials for Usher syndrome and retinitis pigmentosa clinical trials
ProQR's Phase 2/3 trials center around its emerging therapy, ultevursen (previously named QR-421a), and are accepting patients with mutations in exon 13 of the USH2A gene.
Apellis unveils 18-month results from phase 3 OAKS and DERBY studies
According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over time.
Study finds that sound stimulates blind retina to transmit signals to the brain
Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.
Former UCLA faculty member donates $10 million for ocular genetics research
A gift from Bronwyn Bateman, MD, will establish the UCLA Bronwyn Bateman Center for Ocular Genetics at the Stein Eye Institute.
Hospital bombing in Ukraine includes ophthalmology department
Russian bombs on Wednesday struck a hospital in Mariupol, Ukraine, damaging several buildings, including an ophthalmology department. Elsewhere, physicians are participating in relief efforts.
Healthy circadian rhythm may protect aging eyes from retinal degeneration
Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”
Sigma 1 receptor may protect retinal and brain cells impacted by glaucoma
A team of investigators found that sigma 1 receptor, which is known to protect cells from stress, could turn out to be key to the function and survival of the neurons most impacted by glaucoma.
Celebrating 40 years of innovation from Orbis International
40 years after the inaugural flight of the Flying Eye Hospital, Orbis International continues to harness the power of innovation to reach new heights in the fight against avoidable blindness.
March is declared to be Workplace Eye Wellness Month per Prevent Blindness
The group is offering free sight-saving resources to employees and employers.
Phase 2b/3 results for nAMD candidate KSI-301 revealed by Kodiak Sciences
KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks; however, it was safe and well-tolerated with no new or unexpected safety signals.
First successful implantation of wireless visual prosthesis brain implant completed
While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.
PALADIN 3-year results: Fluocinolone acetonide intravitreal implant improves visual acuity, CST
Alimera Sciences, Inc. announces statistically significant improvements in best corrected visual acuity, central subfield thickness and treatment burden for patients with diabetic macular edema.
Monte Carlo simulation indicates positive outcomes for anti-VEGF therapy in severe NPDR
Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.
Inebilizumab-cdon reduces neuromyelitis optica spectrum disorder attack severity
According to data presented by Horizon Therapeutics at the North American Neuro-Ophthalmology Society annual meeting in Austin, Texas, Upliznq treatment is linked to fewer severe attacks and reduced levels of key disease-related biomarkers versus placebo.
Complement-targeted gene therapies for treatment of GA, other ocular diseases licensed by Kriya Therapeutics
Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
FDA grants IND clearance for AffaMed's AM712 to treat retinal vascular diseases
AM712 is a novel bispecific biologic molecule specifically designed for ocular use. In pre-clinical studies, it demonstrated efficacy, ocular pharmacokinetics, and the desired safety profile supporting clinical exploration.
Last patient in Stealth BioTherapeutics Phase 2 geographic atrophy clinical trial completes treatment
According to the company, it is developing elamipretide for treatment of extra-foveal geographic atrophy under U.S. FDA Fast Track designation.
Alzheimer disease: The retina may predict cognitive changes in middle age
Researchers know that parts of the retina are considered as biomarkers for Alzheimer disease, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.
CANDELA Phase 2 results indicate benefits in high dose aflibercept for wet AMD
At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.
UBX1325 Phase 1 study data revealed at Angiogenesis
Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wet AMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
Results for AI algorithm for autonomous screening, detection of diabetic retinopathy reported by AEYE Health
The company noted that the study was the first to evaluate whether AI software can accurately detect more-than-mild diabetic retinopathy using a single image per eye, obtained from either a desktop or handheld retinal camera.
100-week results of KESTREL, KITE push brolucizumab toward FDA approval
Dr. Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular edema.
High dose of THR-149 delivers BCVA increase, stable CST in KALAHARI study
Dr. Arshad M. Khanani reviews the Phase 2 part A results of the KALAHARI study of THR-149 for the treatment of DME.
Detecting diabetic retinopathy with deep learning and ultra-widefield scanning laser ophthalmoscope images
During her talk at Angiogenesis, Dr. Loewenstein outlines how artificial intelligence could revolutionize diabetic retinopathy screening.
Stem cell-derived retinal implant shows long-term viability in new data from USC investigators
The latest invention from Mark S. Humayun, MD, PhD, brings hope to sufferers of age-related macular degeneration, a common type of blindness.
FDA grants Fast Track Designation to NGM Bio’s NGM621
NGM621 is a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.
VIVID/VISTA data study: Baseline factors affect DME resolution
Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.
Spect, MedArrive offer retinal screening options to vulnerable patients
Spect’s mobile device will enable providers to conduct critical eye screenings anywhere in a matter of minutes.
2 Clarke Drive Cranbury, NJ 08512